Table 1 Patient characteristics
Patient characteristics N (%) | Low dose 97 (12.4%) | Intermediate dose 411 (52.8%) | High dose 271 (34.8%) | P value |
|---|---|---|---|---|
Median age (range) years | 54.5 [16–78] | 51 [19–77] | 46 [16–73] | < 0.001 |
Age ≥ 65 years | 22 (22.9%) | 48 (11.9%) | 11 (4.2%) | < 0.001 |
Sex | ||||
Female | 29 (29.9%) | 137 (33.3%) | 74 (27.3%) | 0.243 |
Male | 68 (70.1%) | 274 (66.7%) | 197 (72.7%) | |
Smoking status | ||||
Never | 48 (52.2%) | 261 (67.8%) | 146 (57%) | 0.003 |
Ever | 44 (47.8%) | 124 (32.2%) | 110 (43%) | |
Median pack-year (range) | 14 (7.13, 26.75) | 15 (5, 25) | 14.13 (5.25, 22) | 0.946 |
ECOG status | ||||
0–1 | 57 (95%) | 225 (98.7%) | 182 (98.4%) | 0.167 |
≥ 2 | 3 (5%) | 3 (1.3%) | 3 (1.6%) | |
Baseline mean BMI (±SD) | 23.37 ± 4.2 | 23.47 ± 4.15 | 23.37 ± 4.17 | 0.952 |
< 18.5 | 12 (12.4%) | 25 (6.1%) | 16 (6%) | 0.199 |
18.5–22.9 | 37 (38.1%) | 181 (44.3%) | 123 (45.9%) | |
≥ 23 | 48 (49.5%) | 203 (49.6%) | 129 (48.1%) | |
WHO classification | ||||
I | 0 (0%) | 3 (0.7%) | 7 (2.7%) | 0.147 |
II | 57 (58.8%) | 217 (54%) | 138 (53.7%) | |
III | 40 (41.2%) | 182 (45.3%) | 112 (43.6%) | |
T-stage | ||||
T1–2 | 23 (23.7%) | 96 (23.4%) | 50 (18.5%) | 0.156 |
T3–4 | 73 (75.3%) | 305 (74.2%) | 208 (76.8%) | |
Tx | 1 (1%) | 10 (2.4%) | 13 (4.8%) | |
LN Stage | ||||
0–1 | 34 (35.1%) | 140 (34.1%) | 71 (26.2%) | 0.016 |
2–3 | 63 (64.9%) | 263 (64%) | 187 (69%) | |
Nx | 0 (0%) | 8 (1.9%) | 13 (4.8%) | |
Stage at diagnosis | ||||
I | 0 (0%) | 1 (0.2%) | 1 (0.4%) | 0.029 |
II | 18 (18.6%) | 70 (17%) | 38 (14%) | |
III | 36 (37.1%) | 190 (46.2%) | 124 (45.8%) | |
IVa | 28 (28.9%) | 104 (25.3%) | 54 (19.9%) | |
IVb | 15 (15.5%) | 38 (9.2%) | 41 (15.1%) | |
Unknown | 0 (0%) | 8 (1.9%) | 13 (4.8%) | |
Any comorbidity | 30 (30.9%) | 92 (22.4%) | 57 (21%) | 0.127 |
Cardiac | 6 (6.2%) | 10 (2.4%) | 2 (0.7%) | 0.009 |
Diabetes | 14 (14.4%) | 37 (9%) | 14 (5.2%) | 0.014 |
Hyperlipidemia | 7 (7.2%) | 20 (4.9%) | 16 (5.9%) | 0.622 |
Hypertension | 22 (22.7%) | 68 (16.5%) | 33 (12.2%) | 0.043 |
Kidney Disease | 0 (0%) | 3 (0.7%) | 0 (0%) | 0.260 |
Mean Baseline CCr (±SD) | 81 ± 27 | 92 ± 28 | 129 ± 29 | < 0.001 |
Prophylactic feeding tube | 48 (49.5%) | 201 (48.9%) | 152 (56.1%) | 0.169 |